Predictors of Remission in Acute and Continuation Treatment of Depressive Disorders
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: To identify factors predicting remission of depression during acute (12 weeks) and continuation treatment (12 months) using a 1-year, naturalistic prospective study design. Methods: Patients with depressive disorders were recruited from Chonnam National University Hospital in South Korea from March 2012 to April 2017. At baseline, 1,262 patients received outpatient therapy, and sociodemographic and clinical data were obtained. Clinical visits took place every 3 weeks during the acute treatment phase (at 3, 6, 9, and 12 weeks; n = 1,246), and every 3 months during the continuation treatment phase (at 6, 9, and 12 months; n = 1,015). Remission was defined as a Hamilton Depression Rating Scale score ≤ 7. Results: The remission rate was 43.3% at 12 weeks and 70.4% at 12 months. In multivariate analyses, remission during the acute treatment phase was more likely in patients with a shorter-duration present episode, higher functioning, and good social support. Remission during the continuation treatment phase was more likely in patients with fewer previous depressive episodes and/or a lower baseline stress score. Conclusion: Factors predicting depressive disorder remission may differ between the acute and continuation treatment phases.
Abstract
Objective: To identify factors predicting remission of depression during acute (12 weeks) and continuation treatment (12 months) using a 1-year, naturalistic prospective study design. Methods: Patients with depressive disorders were recruited from Chonnam National University Hospital in South Korea from March 2012 to April 2017. At baseline, 1,262 patients received outpatient therapy, and sociodemographic and clinical data were obtained. Clinical visits took place every 3 weeks during the acute treatment phase (at 3, 6, 9, and 12 weeks; n = 1,246), and every 3 months during the continuation treatment phase (at 6, 9, and 12 months; n = 1,015). Remission was defined as a Hamilton Depression Rating Scale score ≤ 7. Results: The remission rate was 43.3% at 12 weeks and 70.4% at 12 months. In multivariate analyses, remission during the acute treatment phase was more likely in patients with a shorter-duration present episode, higher functioning, and good social support. Remission during the continuation treatment phase was more likely in patients with fewer previous depressive episodes and/or a lower baseline stress score. Conclusion: Factors predicting depressive disorder remission may differ between the acute and continuation treatment phases.
참고문헌 (37)
- "Depression" (2020)[URL]
- Whiteford HA, "Global burden of disease attributable to mental and substance use disorders : findings from the Global Burden of Disease Study 2010", Lancet, 382, pp.1575~1586 (2013)
- Trivedi MH, "Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : implications for clinical practice", Am J Psychiatry, 163, pp.28~40 (2006)
- Dawson MY, "Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis", BMC Fam Pract, 5, pp.19~ (2004)
- Iniesta R, "Combining clinical variables to optimize prediction of antidepressant treatment outcomes", J Psychiatr Res, 78, pp.94~102 (2016)
- Kupfer DJ, "Major depressive disorder : new clinical, neurobiological, and treatment perspectives", Lancet, 379, pp.1045~1055 (2012)
- Carter GC, "Comprehensive review of factors implicated in the heterogeneity of response in depression", Depress Anxiety, 29, pp.340~354 (2012)
- Sakado K, "Perceived parenting pattern and response to antidepressants in patients with major depression", J Affect Disord, 52, pp.59~66 (1999)
- Saghafi R, "Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder", Int J Geriatr Psychiatry, 22, pp.1141~1146 (2007)
- Raskin J, "Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder", Int Psychogeriatr, 20, pp.309~327 (2008)
- Khan A, "Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials", J Psychiatr Res, 39, pp.145~150 (2005)
- Cheng IC, "Predictors of treatment response and length of stay for inpatients with major depression", J Formos Med Assoc, 106, pp.903~910 (2007)
- Andreescu C, "Effect of comorbid anxiety on treatment response and relapse risk in late-life depression : controlled study", Br J Psychiatry, 190, pp.344~349 (2007)
- Russell JM, "Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression", Depress Anxiety, 13, pp.18~27 (2001)
- Kelley ME, "Response rate profiles for major depressive disorder : characterizing early response and longitudinal nonresponse", Depress Anxiety, 35, pp.992~1000 (2018)
- Olgiati P, "Early improvement and response to antidepressant medications in adults with major depressive disorder. Metaanalysis and study of a sample with treatment-resistant depression", J Affect Disord, 227, pp.777~786 (2018)
- Hee-Ju Kang, "The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology", PSYCHIATRY INVESTIGATION, 15(5), pp.538~545 (2018), 대한신경정신의학회
- Sheehan DV, "The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10", J Clin Psychiatry, 59(Suppl 20), pp.22~33 (1998)
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)
- Zigmond AS, "The hospital anxiety and depression scale", Acta Psychiatr Scand, 67, pp.361~370 (1983)
- Rabin R, "EQ-5D : a measure of health status from the EuroQol Group", Ann Med, 33, pp.337~343 (2001)
- Bauer M, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for biological treatment of unipolar depressive disorders, part 1 : update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)
- Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
- Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
- Swift JK, "The impact of client treatment preferences on outcome : a meta-analysis", J Clin Psychol, 65, pp.368~381 (2009)
- Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : a STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
- Nelson JC, "Predictors of remission with placebo using an integrated study database from patients with major depressive disorder", Curr Med Res Opin, 28, pp.325~334 (2012)
- Riedel M, "Clinical predictors of response and remission in inpatients with depressive syndromes", J Affect Disord, 133, pp.137~149 (2011)
- Zisook S, "General predictors and moderators of depression remission : a VAST-D report", Am J Psychiatry, 176, pp.348~357 (2019)
- Rytsälä HJ, "Functional and work disability in major depressive disorder", J Nerv Ment Dis, 193, pp.189~195 (2005)
- Knight MJ, "Cognitive dysfunction in major depressive disorder", Curr Opin Psychiatry, 31, pp.26~31 (2018)
- Sheehan DV, "Restoring function in major depressive disorder : a systematic review", J Affect Disord, 215, pp.299~313 (2017)
- Culpepper L, "Cognitive impairment in patients with depression : awareness, assessment, and management", J Clin Psychiatry, 78, pp.1383~1394 (2017)
- Bosworth HB, "The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults", Int J Geriatr Psychiatry, 23, pp.129~134 (2018)
- Cowan MJ, "Predictors of treatment response for depression and inadequate social support--the ENRICHD randomized clinical trial", Psychother Psychosom, 77, pp.27~37 (2008)
- Johansson O, "12-Month outcome and predictors of recurrence in psychiatric treatment of depression : a retrospective study", Psychiatr Q, 86, pp.407~417 (2015)
- Juruena MF, "Early-life stress and HPA axis trigger recurrent adulthood depression", Epilepsy Behav, 38, pp.148~159 (2014)